- TLDR Biotech
- Archive
- Page 4
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | September 24 - 25, 2024
Emergent raking in $400M in mpox, smallpox vaccine orders, Vertex’s Casgevy approved in Canada, Amgen notches mixed wins in atopic dermatitis and myasthenia graves, Genespire’s $52M Series B, Eurofins to build new $64M biologics site, AskBio’s gene therapy collab with Belief BioMed, semaglutide continues wonder-drug tirade with studies pointing to treating a chronic skin condition and opioid use disorder, 2seventy bio & BMS shutter Abecma myeloma trial, J&J allegedly slashing cardiovascular and metabolic disease divisions, Pfizer’s global recall of Oxbryta sickle cell med due to patient deaths
Biotech & Pharma Updates | September 23 - 24, 2024
Novartis’ $1B+ biobucks deal with Generate:Biomedicines, Capricor stock explodes on cell therapy BLA filing intention, Biogen & UCB's two decade lupus struggle seemingly vindicated with a Ph3 win, Constructive Bio’s $58M Series A for cellular bio factories, cell therapy CDMO Minaris to be acquired by investment firm Altaris, Lonza signs on to manufacture Vertex’s Casgevy CRISPR-based therapy, bluebird and AGC both announces layoffs, Baltimore sues Biogen over alleged PBM “bribes” to stifle MS generic competition
Biotech & Pharma Updates | September 22 - 23, 2024
Sanofi scores first-line multiple myeloma approval, Sanofi buys Ventyx's Parkinson’s, obesity asset for $27M, Teva’s once-monthly schizophrenia med hits safety and efficacy endpoints, ViceBio’s $100M raise for next-gen respiratory illness vaccines, CAMP4 goes for $75M IPO, Telix acquires RLS Radiopharmacies, AstraZeneca & Daiichi’s breast cancer ADC stumbles in Ph3, J&J raises Talc settlement offer to $8B
Biotech & Pharma Updates | September 19 - 22, 2024
FTC sues big three pharmacy benefit managers over insulin prices, AstraZeneca’s (MedImmune) nasal spray flu vaccine scores FDA approval, J&J adds third Rybrevant lung cancer indication, Gilead contracts Yuhan corp for HIV drug ingredient manufacturing, FDA site inspectors hiring ongoing to combat inspection backlog, Novo’s CB1 obesity med takes Ph2 hit over neuropsychiatric side effects, BMS to cut 79 New Jersey-based staffers, Monkey outbreak rages on in Africa
Biotech & Pharma Updates | September 18 - 19, 2024
GC Therapeutics launches with $75M to revolutionize cell therapy, Roche’s positive antiviral Ph3 data, Tanai Therapeutics’ obesity endeavours further fuelled by Novo Nordisk, Upstream Bio files for IPO, Basilea extends BARDA partnership, Vanda’s gastroparesis small molecule rejected by FDA, biotech small-cap market goes “meh” on US Fed rate cut, Achilles axes TIL-based therapy program, study finds new-gen migraine meds not much better than OTC regulars (eg. tylenol, aspirin)
Biotech & Pharma Updates | September 17 - 18, 2024
Novo Nordisk’s $600M biobucks deal with NanoVation Therapeutics, Roivant sells derm division to Organon, Merck’s Keytruda nabs another indication, BMS and Novartis both boast long term MS data, Brenus Pharma $25M Series A for cancer vaccines, Insilico Medicines' dubious clinical efficacy data, Guardant Health CEO calls cap on Exact Science’s blood-based colon cancer test, Novo Nordisk accused of excessive Ozempic price gouging
Biotech & Pharma Updates | September 16 - 17, 2024
Novartis nabs Kisqali label expansion, AC Immune lands $29M Alzheimer’s milestone payment, Merck & Daiichi’s ADC bests chemo in lung cancer Ph3, Cape Fear BioCapital’s new early-stage therapeutic seed fund, Sandoz wins against United Therapeutics in yearslong generics spat, AbbVie & Ripple RTC-620 development partnership, Athira lays off 70%, biopharma mulls advancing Biosecure act, Express Scripts sues FTC over “biased” report
Biotech & Pharma Updates | September 14 - 16, 2024
Novo Nordisk & Korro Bio sign $530M biobucks pact, Eli Lilly nabs FDA eczema approval, Pfizer posts positive cancer cachexia Ph2 data, BMS' impressive 10+ year survival in Ph3 melanoma trial, Nuvalent’s proposed $500M public offering, mRNA COVID-19 vaccines may increase cancer immunotherapy effectiveness, Intercept’s Ocaliva faces FDA adcomm ire, BMS walks from $150M Immatics bispecific wager
Biotech & Pharma Updates | August 29 - September 1, 2024
Novo's Wegovy could prevent death by heart failure & COVID-19, Ipsen sells priority review voucher for $158M, EVOQ Therapeutics lands $2M NIH grant, NIH earmarks $22M for extremophile research, Alnylam heart disease Ph3 succeeds but disappoints, Biosecure Act up for House vote this month.
Biotech & Pharma Updates | August 28 - 29, 2024
J&J aims for "broadest" nipocalimab FDA approval, AbbVie's positive Ph3 Ubrelvy data in migraine prevention, Catalent beats H1 2024 revenue estimates as Novo acquisition approaches, conglomerate Lotte launches biopharma VC division, Qiagen and AstraZeneca partner on companion diagnostics, BioMarin and Repare both cut staff, API manufacturer Global Calcium handed FDA Form 483
Biotech & Pharma Updates | August 27 - 28, 2024
Pfizer, Bayer, and Novartis all sign big partnerships, Astellas' Padcev+Keytruda combo nabs EC approval, Novartis' Leqvio Ph3 data sets stage for label expansion, UK gov launches £400M ($527M) biopharma public-private investment program, NIH launches $270M anti-overdose research program focused on Native American population, Regeneron sues Sandoz over alleged biosimilar patent infringement, Genentech to lay off 93 staffers in SF, EyePoint handed an FDA Warning Letter
Biotech & Pharma Updates | August 26 - 27, 2024
Eli Lilly offers discounted Zepbound, Pfizer officially launches DTC service, a pair of CAR-T cell therapies land China NMPA approval, Navigator Medicines launches with $100M and an in-licensed bispecific antibody, Elektrofi raises $96M of $112M Series C, AstraZeneca's $135M Sweden manufacturing site expansion, trade group BIO pens amicus brief against IRA, Emergent lays off 70 staffers, Sanofi halts China flu vaccine rollouts due to declining potency concerns